Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,216,925.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $549.15, for a total value of $5,216,925.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,247,713.95. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Down 2.7%

UTHR stock opened at $536.59 on Friday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock’s 50 day moving average is $565.37 and its 200-day moving average is $523.32. The firm has a market capitalization of $22.78 billion, a PE ratio of 19.81, a P/E/G ratio of 1.80 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. During the same period in the previous year, the firm earned $6.63 EPS. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in UTHR. Torren Management LLC purchased a new stake in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management boosted its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $31,000. International Assets Investment Management LLC grew its position in shares of United Therapeutics by 426.7% during the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB grew its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent analyst reports. HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.